Us Congress 2025-2026 Regular Session

Us Congress Senate Bill SB780

Introduced
2/27/25  

Caption

SAFE Lending Act of 2025 Stopping Abuse and Fraud in Electronic Lending Act of 2025

Congress_id

119-S-780

Policy_area

Finance and Financial Sector

Introduced_date

2025-02-27

Companion Bills

US HB1658

Related bill SAFE Lending Act of 2025 Stopping Abuse and Fraud in Electronic Lending Act of 2025

Similar Bills

US HB2618

Federal Firearm Licensee Act

US SB1053

FIGHT China Act of 2025 Foreign Investment Guardrails to Help Thwart China Act of 2025

US HB2548

Sanctioning Russia Act of 2025

US SB1241

Sanctioning Russia Act of 2025

US HB1398

Securing Strictly Needy Americans’ Pivotal (SNAP) Benefits Act of 2025

US HB654

TABS Act of 2025 Taking Account of Bureaucrats’ Spending Act of 2025

US SB331

Halt All Lethal Trafficking of Fentanyl Act or the HALT Fentanyl ActThis bill permanently places fentanyl-related substances as a class into schedule I of the Controlled Substances Act. A schedule I controlled substance is a drug, substance, or chemical that has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act.Under the bill, offenses involving fentanyl-related substances are triggered by the same quantity thresholds and subject to the same penalties as offenses involving fentanyl analogues (e.g., offenses involving 100 grams or more trigger a 10-year mandatory minimum prison term).Additionally, the bill establishes a new, alternative registration process for certain schedule I research.The bill also makes several other changes to registration requirements for conducting research with controlled substances, includingpermitting a single registration for related research sites in certain circumstances,waiving the requirement for a new inspection in certain situations, andallowing a registered researcher to perform certain manufacturing activities with small quantities of a substance without obtaining a manufacturing registration.Finally, the bill expresses the sense that Congress agrees with the interpretation of the Controlled Substances Act in United States v. McCray, a 2018 case decided by the U.S. District Court for the Western District of New York. In that case, the court held that butyryl fentanyl, a controlled substance, can be considered an analogue of fentanyl even though, under the Controlled Substances Act, the term controlled substance analogue specifically excludes a controlled substance.

US SB467

End Double Taxation of Successful Consumer Claims Act